Peptides for body recomposition FAQ

Reduce injection frequency to every other day for 7–10 days, then resume daily dosing. GH receptor desensitization occurs when receptors are continuously occupied. Pulsatile administration prevents this, but even pulsatile protocols can benefit from periodic breaks. The plateau likely reflects receptor downregulation rather than peptide degradation, so 'cycling off' for a week restores sensitivity without losing previous progress. During the break, maintain protein intake at 1.8–2.2 g/kg body weight and keep training volume unchanged. Lean mass retention during the break depends on mechanical tension (training stimulus) and amino acid availability, not continuous peptide administration.

Discard the vial. Do not attempt to use it. Lyophilized peptides tolerate ambient temperature before reconstitution, but once mixed with bacteriostatic water, they require refrigeration at 2–8°C. A single temperature excursion above 8°C for more than 2 hours causes protein denaturation, where the peptide's three-dimensional structure unfolds and loses receptor-binding capability. The solution may appear unchanged (clear, no precipitate), but biological activity is compromised or absent. Research institutions using peptides in controlled studies discard any vial with documented temperature deviation. The financial cost of a replacement vial is negligible compared to weeks of ineffective dosing.

MK-677 transiently elevates fasting glucose by 5–10 mg/dL in approximately 30% of users due to GH's counter-regulatory effects on insulin. If fasting glucose exceeds 110 mg/dL or HbA1c trends upward, add berberine 500 mg twice daily with meals or reduce MK-677 dose from 25 mg to 12.5 mg. The glucose elevation is not pathological insulin resistance. It's a pharmacological effect of elevated GH blunting insulin's glucose-lowering action. Most research protocols monitoring glucose continuously found the elevation stabilized within 4–6 weeks and reversed entirely upon cessation. If glucose remains elevated beyond 6 weeks or exceeds 120 mg/dL fasting, discontinue MK-677 and consult a prescribing physician.

True recomposition at maintenance calories (zero net weight change while fat decreases and muscle increases) is biochemically difficult but achievable with precise peptide selection. The protocol requires compounds that enhance nutrient partitioning—shifting ingested calories toward muscle protein synthesis rather than fat storage. Research using MK-677 (a ghrelin mimetic) at 25 mg daily demonstrated this exact outcome: subjects maintained stable body weight over 16 weeks while DEXA scans showed 1.1 kg lean mass gain and 1.3 kg fat mass loss. The mechanism involves elevated IGF-1 driving muscle protein synthesis while increased growth hormone pulses enhance lipolysis during fasted periods. Maintenance recomposition requires higher protein intake (2.2–2.6 g/kg) and progressive resistance training—the peptides create the hormonal environment, but mechanical tension and amino acid availability are what actually build tissue.

Yes, but the mechanism shifts. At body fat levels below 12% (men) or 20% (women), the body's adaptive responses to caloric deficit become more aggressive—leptin drops sharply, ghrelin stays elevated longer, and thyroid output decreases to preserve remaining fat stores. GH secretagogues become particularly valuable at this stage because they maintain IGF-1 levels that would otherwise crash, preventing muscle catabolism even as fat loss slows. Research using ipamorelin in lean subjects (BMI 20–23) showed that lean mass was preserved even during 20% caloric deficits sustained for eight weeks, whereas control groups lost measurable muscle mass. The fat loss rate was slower than in higher-body-fat subjects, but the recomposition ratio (percentage of weight lost coming from fat vs muscle) was actually better—94% fat vs 6% lean compared to 85% fat vs 15% lean in subjects starting above 25% body fat.

Combining peptide classes with different mechanisms generally shows additive effects rather than antagonism, but timing and receptor saturation matter. Pairing a GH secretagogue (ipamorelin) with a GLP-1 agonist (tirzepatide) works because they target different pathways—one maintains anabolic signaling, the other drives appetite regulation and fat oxidation. However, combining two GH secretagogues that both act on the ghrelin receptor (like GHRP-6 and ipamorelin) may not produce proportionally greater GH release because you're saturating the same receptor pool. The most effective stacks in published research pair compounds with complementary mechanisms: GH secretagogue + GLP-1 agonist + beta-adrenergic activator. One interaction to watch: GLP-1 agonists slow gastric emptying, which can delay absorption of orally administered peptides—subcutaneous administration avoids this issue entirely.

Reduce MK-677 dose to 12.5mg daily or switch to an every-other-day protocol to blunt ghrelin receptor activation while maintaining baseline IGF-1 elevation. Alternatively, replace MK-677 with a pure GHRH analog like CJC-1295/Ipamorelin, which doesn't stimulate appetite but still amplifies GH pulses. The appetite effect diminishes after 2–3 weeks in most users as ghrelin receptor desensitisation occurs, so short-term hunger doesn't necessarily predict long-term adherence issues.

Recomposition is slow. Visual changes lag behind measurable shifts in lean mass and body fat percentage by 6–8 weeks in most cases. Verify that your protocol includes all three pillars: peptide administration, resistance training volume of 10–20 sets per muscle group weekly, and protein intake of 1.6–2.2g/kg. If all three are in place and body composition remains static, consider that you may be in a true maintenance state where muscle gain and fat loss are occurring at equal rates. Scale weight won't change, but body measurements and strength progression will. DEXA scans or bioimpedance analysis every 4–6 weeks provide clearer feedback than visual assessment alone.

Peptides enhance recovery capacity but don't eliminate the need for adequate sleep, protein, and periodisation. If volume tolerance hasn't improved after 3–4 weeks on a GH secretagogue, assess sleep quality first. Growth hormone's anabolic effects depend on slow-wave sleep, which is disrupted by poor sleep hygiene, caffeine late in the day, or inadequate magnesium intake. Adding recovery-focused peptides like BPC-157 or TB-500 can support tendon and connective tissue adaptation, allowing you to sustain higher mechanical load without overuse injuries.

AOD-9604 and MOTS-c are ideal because neither affects insulin or glucose metabolism. AOD-9604 acts exclusively on adipose tissue via beta-3 adrenergic receptors, and MOTS-c actually improves insulin sensitivity by activating AMPK and increasing glucose uptake in skeletal muscle. Avoid IGF-1 LR3 in this context. It can cause hypoglycemia in insulin-resistant individuals due to direct insulin-like effects on glucose uptake. GH secretagogues (CJC-1295, Ipamorelin, MK-677) are generally safe but should be monitored. GH is mildly insulin-antagonistic, meaning it can raise fasting glucose slightly in predisposed individuals.

Increase the lipolytic stimulus by adding a metabolic modulator like AOD-9604 or MOTS-c. GH secretagogues elevate GH and IGF-1, but if you're in a caloric surplus or consuming high insulin-spiking meals around dosing windows, the anabolic signal dominates and fat oxidation is suppressed. GH stimulates lipolysis only in a low-insulin state. If insulin is elevated, hormone-sensitive lipase (the enzyme that breaks down triglycerides) is inhibited regardless of GH levels. The solution is either tighter dietary control (fasted cardio post-injection, carbohydrate timing away from GH pulses) or the addition of a peptide that bypasses insulin signaling entirely, like AOD-9604.

MK-677 is the only orally bioavailable GH secretagogue with clinical evidence for body composition changes. Most peptides are degraded by gastric enzymes and require subcutaneous or intramuscular injection. 5-Amino-1MQ and Tesofensine are orally active, but they're metabolic modulators rather than direct GH or IGF-1 elevators. If injections are non-negotiable, your recomposition protocol is limited to MK-677 (for anabolism) plus 5-Amino-1MQ or Tesofensine (for fat oxidation), with the understanding that results will be slower and less dramatic than injectable protocols.

MK-677's appetite-stimulating effect is driven by ghrelin receptor activation in the hypothalamus and gut. If you're eating in a surplus, the GH elevation will drive anabolism, but excess calories will still be stored as fat. The fix is either stricter caloric tracking (weighing food, tracking macros) or switching to a non-appetite-stimulating GH protocol like CJC-1295/Ipamorelin. Alternatively, stack MK-677 with Tesofensine or a GLP-1 analog to offset the appetite increase. The thermogenic and satiety effects counterbalance ghrelin-driven hunger.